GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pharmadrug PHRX.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.01

0.00%

Close of 5 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Pharmadrug

Its shares trade on Canadian Securities Exchange under the ticker PHRX.CN. It has been listed since 16 August 2018. In the fiscal year to 31 December 2021, it reported revenue of C$7,009 and a net loss of C$5.9m. At that date it held total assets of C$19.5m and shareholders' equity of C$16.9m.

Pharmadrug Inc is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-08-16. PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The firm is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
16 Aug 2018

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Pharmadrug Inc focuses on controlled-substances and natural medicines including psychedelics.
  • Sairiyo Therapeutics develops patented reformulation of cepharanthine for infectious diseases.
  • Cepharanthine shows multiple pharmacological effects like anti-viral and anti-cancer properties.

Weaknesses

  • Pharmadrug Inc operates in a highly regulated pharmaceutical industry.
  • Sairiyo Therapeutics' R&D in psychedelics faces regulatory hurdles.
  • Pharmadrug Inc's focus on natural medicines may limit market reach.

Opportunities

  • Cepharanthine's potential for treating Covid-19 offers significant market opportunity.
  • Sairiyo's reformulation of cepharanthine could expand into rare cancer treatments.
  • Psychedelics research for non-neuropsychiatric conditions presents new growth areas.

Threats

  • Regulatory challenges in the controlled-substances sector may delay product launches.
  • Competition in the natural medicines market could reduce market share.
  • Economic downturns might affect investment in R&D for new treatments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.